Cite
HARVARD Citation
Chau, I. et al. (n.d.). 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment. European journal of cancer. pp. S446-. [Online].